Skip to main content

Cloud Edge and IoT will Improve Pharma Manufacturing

The global COVID-19 pandemic has accelerated changes in many industries. One of the most impacted was the pharmaceutical sector that had to reimagine business processes and rapidly adopt new technologies. It's yet another example where applying cloud computing had become a strategic imperative.

Today, next-generation pharma concepts are fueling ongoing innovation. In particular, the industry’s unique characteristics are driving investments in Digital Transformation by forward-looking pharmaceutical manufacturers. 

According to the latest worldwide market study by ABI Research, digital factory revenue will top $4.5 billion in 2030 with spending by pharma manufacturers on data analytics forecast to grow by a 27 percent CAGR and reach $1.2 billion in 2030, as these companies evolve to boost productivity.

Pharma Digital Transformation Market Development

That said, the industry’s competitive dynamics require pharmaceutical firms to optimize their production lines to maximize yield for the time a drug has patent protection. After patents expire, generics companies will produce similar products.

According to the ABI assessment, the utilization of data analytics can support each type of effort to increase yield. Moving from manufacturing drugs and vaccines in batches, to optimizing the manufacturing process with 'continuous production' can dramatically increase yields.

"But the active pharmaceutical ingredients are susceptible to changes in their immediate environment. The batch must be scrapped if the condition of the ingredients or formulation falls outside accepted parameters," says Michael Larner, principal analyst at ABI Research.

Therefore, pharma manufacturers can choose to invest in analytics that aid in the development of 'digital twins' of their operations, so that they can prepare their production lines for more predictable continuous manufacturing.

Another digitization focus for pharmaceutical firms is to remove paper recordkeeping. "Collecting and storing data via paper-based processes risks reducing productivity and increases the likelihood that errors happen on the production line due to administrative errors," Larner points out.

FDA 21 CFR Part 11 is one way the U.S. Food and Drug Administration is encouraging the adoption of digital technologies by publishing the criteria for submitting electronic records to the organization and the treatment of electronic signatures.

The prevalence of paper records illustrates the progress yet to be made by pharmaceutical firms regarding digital transformation. ABI Research has offered a five-stage 'digital maturity' model, outlining the progress made and steps required by drug manufacturers to optimize their operations.

Larner explains, "Currently, pharmaceutical manufacturers are at Stage 2 in that they have modern factory but lack foresight and struggle to adjust production, or Stage 3 where they have started to implement digital transformation but lack expertise reconfiguring production lines."

In the coming decade, many firms will upgrade their existing facilities or build new 'greenfield' manufacturing sites, and their operations will be digitally transformed (Stage 4) or operate without humans on-site (Stage 5).

A notable example of advanced manufacturing facilities is Sanofi’s digitally-enabled, continuous manufacturing facility in Framingham, Massachusetts where all processes are paperless with plant operators using digital collaboration tools, data analytics, and Augmented Reality (AR) solutions so they can make decisions and adjustments in real-time.

Outlook for Digital Transformation in Pharma

ABI analysts say that there is already a myriad of suppliers helping the pharma industry to digitize and optimize processes by moving from the pre-digital stage (Stage 1) to connecting their manufacturing plants (Stage 3).

Moreover, I believe that the introduction of advances within the Internet of Things (IoT) arena -- and the introduction of fifth-generation (5G) wireless infrastructure and cloud edge computing solutions -- will enable the development of automated production processes and eventually new business models.

It's estimated that the COVID-19 pandemic has already fast-forwarded the digital transformation of the pharma industry by more than five years. Cloud computing and cloud-based IT security solutions helped CIOs and CTOs to adopt 'remote working' and perform decentralized clinical trials of vaccines.

Indeed, the path ahead for continued progress looks bright. And, I'm encouraged by these latest research findings. I'll share more insights on this topic as they're announced by the leading industry analysts.

Popular posts from this blog

Digital Transformation Growth Defies Market Volatility

The forward-looking CEO's commitment to ongoing investment in Information Technology (IT) is persistent. Worldwide IT spending is forecast to total $4.4 trillion in 2022 -- that's an increase of 4 percent from 2021, according to the latest worldwide market study by Gartner, Inc.   "This year is proving to be one of the noisiest years on record for CIOs," said John-David Lovelock, vice president at Gartner . Regardless, digital transformation remains a high priority across the globe. Geopolitical disruption, inflation, currency fluctuations, and supply chain challenges are among the many market volatility factors vying for attention, yet contrary to what Gartner saw at the start of 2020, enterprise CIOs are accelerating IT investments in 2022. Digital Transformation Market Development As a result, purchasing and investing preferences will be focused on areas including data analytics, cloud computing, seamless customer experiences, and IT security. Inflation impacts on

IoT Device Management Demand Gains Momentum

More forward-thinking CIOs and CTOs are focused on the adoption of the Internet of Things (IoT). Management challenges are top of mind for those who have already deployed a large number of sensors and associated network edge devices. Device management services are evolving in response to a greater breadth of new device technologies such as edge intelligence and related connectivity solutions, as well as the customer scalability and security of IoT deployments. But forward-looking suppliers are also preparing for a world where 41.3 percent of the connected devices will be using some form of Low Power Wide Area (LPWA) technologies by 2026. IoT Device Management Market Development Since IoT customers increasingly need to manage a larger fleet of connected devices, ABI Research now forecasts that IoT device management services will exceed $36.8 billion in revenues by 2026. Standardization is beginning to play a bigger role in device management services, as more connected devices use LPWA t

Anywhere, Anytime Workplace Demand for SASE

The ongoing adoption of flexible working models within the enterprise market has significant implications for typical IT organizations that must now support knowledge workers and front-line employees that operate outside the corporate network perimeter. The global COVID-19 pandemic created IT networking and security challenges. The expansion of the distributed workforce, an increasing reliance on cloud computing infrastructure, and the requirement to securely connect online employees -- wherever they choose to work, at any given moment in time. Legacy IT solutions that have rigid network underlays and a requirement for on-premises infrastructure cannot adequately deal with these trends. This 'Anywhere, Anytime Workplace' led to demand for new Secure Access Service Edge (SASE) solutions, with networking and security delivered as-a-service. Anywhere, Anytime Workplace Market Development   Although converging networking and security capabilities offer enterprises a promising solut